NDATRANSDERMALGEL
Approved
Feb 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ANDROGEL (testosterone) by Besins Healthcare is androgen receptor agonists [moa]. First approved in 2000.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANDROGEL is a transdermal testosterone gel indicated for testosterone replacement therapy in hypogonadal men. It works as an androgen receptor agonist to restore physiologic testosterone levels. The product has been on the market since 2000 and represents a foundational hormone replacement therapy option.
$0.002BPart D
LOE ApproachingProduct is approaching loss of exclusivity with modest Part D spending ($2M) and low claim volume (1,947), signaling a mature/declining brand with likely workforce contraction.
Mechanism of Action
Androgen Receptor Agonists
Pharmacologic Class:
Androgen
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial
Started Oct 2027
300 enrolled
Spinal Cord InjurySpinal Cord InjuriesInjuries, Spinal Cord+11 more
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Started Jun 2026
0Multiple SclerosisErectile DysfunctionTestosterone Deficiency
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Started Mar 2026
60 enrolled
Metastatic Castration-resistant Prostate Cancer
Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury
Started Jul 2025
48 enrolled
Spinal Cord InjuriesEndothelial DysfunctionTestosterone Deficiency
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Started Mar 2025
100 enrolled
Hypogonadism, Male
Worked on ANDROGEL at Besins Healthcare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.